Background: Peptide-linked degradation products of advanced glycation end products (AGE peptides) accumulate in chronic haemodialysis (HD) patients and may contribute to a number of HD-related long-term complications, such as accelerated atherosclerosis. Methods: The influence of a single HD session versus long-term HD on serum AGE peptides was determined. The patients were randomized to HD with a low-flux polysulfone (PS; F 6HPS), a high-flux PS (F 60S), a superflux PS (F 500S), or a superflux cellulose triacetate (CTA; Tricea 150G) dialyzer. Results: During a single HD session, both AGE peptides and reference peptides decreased significantly (AGE peptides: Tricea 150G –37.0 ± 2.9%; F 6HPS –35.5 ± 2.4%; F 60S –39.5 ± 4.7%, and F 500S –43.3 ± 2.1%, p = 0.005; reference peptides: Tricea 150G –73.2 ± 8.8%; F 6HPS –73.2 ± 7.9%; F 60S –72.5 ± 8.2%, and F 500S –74.1 ± 7.3%, p = 0.005). After 12 weeks of HD with the superflux CTA, the AGE peptide levels decreased significantly (week 1: 2.7 ± 1.1 arbitrary units, week 12: 2.5 ± 1.2 arbitrary units, decrease 7.4%; p = 0.01), whereas the AGE peptide levels remained unchanged after HD with each of the other three modalities. The reference peptide levels did not change after 12 weeks of HD. Conclusion: Although AGE peptides can be effectively removed during a single HD session, superflux CTA seems to be the only modality capable of reducing AGE peptides in the long term.

Keywords:
Advanced glycation end products, Renal failure, Haemodialysis, advanced glycation end products, Low-flux dialyzer, High-flux dialyzer, Superflux dialyzer, Long-term results, different haemodialysis modalities
1.
Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S: Uremic toxicity: The middle molecule hypothesis revisited. Semin Nephrol 1994;14:205–218.
2.
Vanholder R: Uremic toxins. Adv Nephrol Necker Hosp 1997;26:143–163.
3.
Vanholder R, De Smet R, Lameire N: Protein-bound uremic solutes: The forgotten toxins. Kidney Int Suppl 2001;78:S266–S270.
4.
Vlassara H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994;12:54–59.
5.
Ritz E, Deppisch R, Nawroth P: Toxicity of uraemia – does it come from AGE? Nephrol Dial Transplant 1994;9:1–2.
6.
Clark WR, Henderson LW: Renal versus continuous versus intermittent therapies for removal of uremic toxins. Kidney Int Suppl 2001;78:S298–S303.
7.
Babb AL, Popovich RP, Christopher TG, Scribner BH: The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 1971;17:81–91.
8.
Deuther-Conrad W, Franke S, Sommer M, Henle T, Stein G: Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. Kidney Int Suppl 2001;78:S63–S66.
9.
Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519–1522.
10.
Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836–842.
11.
Zoccali C, Mallamaci F, Tripepi G: AGEs and carbonyl stress: Potential pathogenetic factors of long-term uraemic complications. Nephrol Dial Transplant 2000;15(suppl 2):7–11.
12.
Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: A nephrologist’s perspective. Am J Kidney Dis 2000;35:365–380.
13.
Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of ‘carbonyl stress’ in long-term uremic complications. Kidney Int 1999;55:389–399.
14.
Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–1321.
15.
Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96:1395–1403.
16.
Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou XS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889–9897.
17.
Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441–9445.
18.
Yoshida S, Yamada K, Hamaguchi K, Nishimura M, Hatakeyama E, Tsuchida H, Sakamoto K, Kashiwabara H, Yokoyama T, Ikeda K, Horiuchi S: Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissue of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 1998;49:273–280.
19.
Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y: Amyloid β2-microglobulin is modified with imidazalone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997;51:187–194.
20.
Nokura K, Koga H, Yamamoto H, Kimura A, Tamai H, Yazaki S, Suzuki N, Miyazaki S, Niwa T: Dialysis-related spinal canal stenosis: A clinicopathological study on amyloid deposition and its AGE modification. J Neurol Sci 2000;178:114–123.
21.
Dawnay A, Miller DJ: The pathogenesis and consequences of AGE formation in uraemia and its treatment. Cell Mol Biol (Noisy-le-Grand) 1998;44:1081–1094.
22.
Schinzel R, Münch G, Heidland A, Sebekova K: Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001;87:295–303.
23.
Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H: Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997;52:1645–1650.
24.
Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, van Ypersele de Strihou C, Miyata T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of ‘carbonyl stress’. Kidney Int 1999;55:2487–2492.
25.
Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999–1008.
26.
Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U: Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002;17:871–878.
27.
Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW: Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003;42:524–531.
28.
Wróbel K, Wróbel K, Garay-Sevilla ME, Nava LE, Malacara JM: Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 1997;43:1563–1569.
29.
Daugirdas JT: Chronic hemodialysis prescription; in Daugirdas JT (ed): Handbook of Dialyis. Boston, Little, Brown, 1994.
30.
Vanholder R, De Smet R, Vogeleere P, Ringoir S: Middle molecules: Toxicity and removal by hemodialysis and related strategies. Artif Organs 1995;19:1120–1125.
31.
Dhondt A, Vanholder R, Van Biesen W, Lameire N: The removal of uremic toxins. Kidney Int Suppl 2000;76:S47–S59.
32.
Gerdemann A, Lemke HD, Nothdurft A, Heidland A, Münch G, Bahner U, Schinzel R: Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 2000;54:276–283.
33.
Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994;46:216–222.
34.
Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodialfiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Transplant 2002;17:1045–1049.
35.
Weiss MF, Rodby RA, Justice AC, Hricik DE: Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group. Kidney Int 1998;54:193–202.
36.
Clark WR, Hamburger RJ, Lysaght MJ: Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 1999;56:2005–2015.
37.
Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000;57:2571–2585.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.